Clinical Trial Update: Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating a dual-targeting PET imaging agent that binds integrin αvβ3 and GRPR in breast cancer patients; the current status is not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dual Integrin αvβ3 and GRPR Targeting PET Imaging Agent

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Breast Cancer | Phase 1 | Status: UNKNOWN